Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men

Jessica A Kahn; Marvin Belzer; Xiaofei Chi; Jeannette Lee; Aditya H Gaur; Kenneth Mayer; Jaime Martinez; Donna C Futterman; Elizabeth A Stier; Mary E Paul; Elizabeth Y Chiao; Daniel Reirden; Steven E Goldstone; Ana P Ortiz Martinez; Edward R Cachay; Luis F Barroso; Maria Da Costa; Craig M Wilson; Joel M Palefsky; AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions

doi:10.1016/j.pvr.2019.01.002

Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men

Papillomavirus Res. 2019 Jun:7:52-61. doi: 10.1016/j.pvr.2019.01.002. Epub 2019 Jan 15.

Authors

Jessica A Kahn¹, Marvin Belzer², Xiaofei Chi³, Jeannette Lee⁴, Aditya H Gaur⁵, Kenneth Mayer⁶, Jaime Martinez⁷, Donna C Futterman⁸, Elizabeth A Stier⁹, Mary E Paul¹⁰, Elizabeth Y Chiao¹¹, Daniel Reirden¹², Steven E Goldstone¹³, Ana P Ortiz Martinez¹⁴, Edward R Cachay¹⁵, Luis F Barroso¹⁶, Maria Da Costa¹⁷, Craig M Wilson¹⁸, Joel M Palefsky¹⁹; AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions

Affiliations

¹ Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA. Electronic address: [email protected].
² Department of Pediatrics, University of Southern California, Los Angeles, CA, USA. Electronic address: [email protected].
³ Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: [email protected].
⁴ Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: [email protected].
⁵ Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: [email protected].
⁶ Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: [email protected].
⁷ John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA. Electronic address: [email protected].
⁸ Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: [email protected].
⁹ Boston University School of Medicine, Boston, MA, USA. Electronic address: [email protected].
¹⁰ Baylor College of Medicine, Houston, TX, USA. Electronic address: [email protected].
¹¹ Baylor College of Medicine, Houston, TX, USA. Electronic address: [email protected].
¹² Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: [email protected].
¹³ Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: [email protected].
¹⁴ Cancer Control and Population Sciences Program, University of Puerto Rico, San Juan, PR, USA. Electronic address: [email protected].
¹⁵ Department of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, CA, USA. Electronic address: [email protected].
¹⁶ Department of Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA. Electronic address: [email protected].
¹⁷ Department of Medicine, University of California San Francisco, San Francisco, CA, USA. Electronic address: [email protected].
¹⁸ Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: [email protected].
¹⁹ Department of Medicine, University of California San Francisco, San Francisco, CA, USA. Electronic address: [email protected].

Abstract

The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants' mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11-6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03-5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16-10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. CLINICAL TRIAL NUMBER: NCT01209325.

Keywords: Adolescents; Clinical trials; HIV; Human papillomavirus; Men who have sex with men; Vaccine.

Publication types

Clinical Trial, Phase II
Multicenter Study
Research Support, N.I.H., Extramural

MeSH terms

Adolescent
Adult
Anal Canal / virology*
Genitalia, Male / virology*
HIV Infections / complications*
Homosexuality, Male*
Humans
Male
Mouth / virology*
Papillomaviridae / classification
Papillomaviridae / isolation & purification*
Papillomavirus Infections / epidemiology*
Prevalence
Young Adult

Associated data

ClinicalTrials.gov/NCT01209325

Abstract

Publication types

MeSH terms

Associated data

Grants and funding